Evidence map›Paper›PMID 29567340›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

William A Wood, Ruta Brazauskas, Zhen-Huan Hu, Hisham Abdel-Azim, Ibrahim A Ahmed, Mahmoud Aljurf, Sherif Badawy, Amer Beitinjaneh, Biju George, David Buchbinder and 40 more

Open access · hybridAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology. American Society of Hematology. Education Program · 2021
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 20 institutions in 11 countries.

William A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina. Electronic address: wawood@med.unc.edu.
Ruta BrazauskasCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
Zhen-Huan HuCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Hisham Abdel-AzimDivision of Hematology, Oncology, and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Ibrahim A AhmedDepartment of Hematology, Oncology, and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Sherif BadawyDivision of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Amer BeitinjanehDepartment of Hematology/Oncology, University of Miami, Miami, Florida.
Biju GeorgeChristian Medical College, Vellore, India.
David BuchbinderDivision of Pediatric Hematology, Children's Hospital of Orange County, Orange, California.
Jan CernyDivision of Hematology/Oncology, UMass Memorial Medical Center, Worcester, Massachusetts.
Laurence DedekenDepartment of Hematology Oncology, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
Miguel Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
Cesar O FreytesTexas Transplant Institute, San Antonio, Texas.
Siddhartha GangulyBlood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.
Usama GergisHematolgic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
David Gomez AlmaguerHospital Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Ashish GuptaSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Gregory HaleDepartment of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
Shahrukh K HashmiDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota; Oncology Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Kehinde AdekolaDivision of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Tamila Kindwall-KellerDivision of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia.
Jennifer KnightDepartment of Psychology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Lalit KumarDepartment of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Yachiyo KuwatsukaCenter for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Jason LawDepartment of Pediatrics, Floating Hospital for Children, Tufts Medical Center, Boston, Massachusetts.
Hillard M LazarusSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Charles LeMaistreHematology and Bone Marrow Transplant, Sarah Cannon, Nashville, Tennessee.
Richard F OlssonDivision of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
Michael A PulsipherDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Kirk R SchultzDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.
Ayman A SaadDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Matthew SeftelDepartment of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Canada.
Sachiko SeoDepartment of Hematology and Oncology, National Cancer Research Center East, Chiba, Japan.
Thomas C SheaDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Amir SteinbergDepartment of Hematology-Oncology, Mount Sinai Hospital, New York, New York.
Keith SullivanDuke University Medical Center, Durham, North Carolina.
David SzwajcerDepartment of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Canada.
Baldeep WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
Jean YaredBlood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.
Agnes YongRoyal Adelaide Hospital/SA Pathology and School of Medicine, University of Adelaide, Adelaide, Australia.
Jignesh DalalSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Theresa HahnDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
Carmem BonfimHospital de Clinicas-Federal University of Parana, Curitiba, Brazil.
Yoshiko AtsutaCenter for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Medical College of Wisconsin · USUniversity Hospitals Seidman Cancer Center · USCancerCare Manitoba · CANagoya University · JPUniversity of North Carolina at Chapel Hill · USUniversity of Southern California · USBaylor College of Medicine · USChildren's Hospital of Orange County · USChildren's Mercy Hospital · USChristian Medical College, Vellore · INCHRISTUS Transplant Institute · USCornell University · USDR. B.R.A. Institute Rotary Cancer Hospital · INDuke Medical Center · USHospital de Clínicas Universidade Federal do Paraná · BRHospital Infantil Universitario Niño Jesús · ESJohns Hopkins University · USKing Faisal Specialist Hospital & Research Centre · SALurie Children's Hospital · USMayo Clinic · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
AHRQ HHS K12 HS023011NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions on post-transplantation outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. Using data from the Center for Blood and Marrow Transplant Research, we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013. Cox regression models were constructed using the following macroeconomic indicators as main effects: Gross national income per capita, health expenditure per capita, and Human Development Index (HDI). The outcome was overall survival at 100 days following transplantation. In each model, transplants performed within lower resourced environments were associated with inferior overall survival. In the model with the HDI as the main effect, transplants performed in the lowest HDI quartile (n = 697) were associated with increased hazard for mortality (hazard ratio, 2.42; 95% confidence interval, 1.64 to 3.57; P < .001) in comparison with transplants performed in the countries with the highest HDI quartile. This translated into an 11% survival difference at 100 days (77% for lowest HDI quartile versus 88% for all other quartiles). Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL. The reasons for this disparity require further investigation.

Indexed as

AdolescentFemaleHematopoietic Stem Cell TransplantationHumansMalePrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisTransplantation ConditioningBone marrowHealth expendituresHematopoietic stem cell transplantationOutcome assessment (Health care)Precursor cell lymphoblastic leukemia-lymphoma

Identifiers

PMID29567340
PMCPMC6146070
OpenAlexW2792892646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.